Michael Gelband’s Immunic IMUX Stock Holding History

Michael Gelband’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,529	Closed	-$244K	–	2564
2021 Q1	$244K	Buy	+1,529	New	+$259K	﹤0.01%	1781
2020 Q3	–	Sell	-1,064	Closed	-$129K	–	1975
2020 Q2	$129K	Buy	+1,064	New	+$108K	﹤0.01%	1604

Other funds holding IMUX

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's IMUX Position: Q2 2021 in Review

Michael Gelband sold out of Immunic (IMUX) in Q2 2021, closing a stake of 1,529 shares — an estimated $244K sold.

Michael Gelband first reported a position in IMUX in Q2 2020 and held it in 2 quarters. The position peaked at $244K in Q1 2021. 60 funds tracked by Wall St. Rank hold IMUX as of Q2 2021.

Michael Gelband reported no remaining Immunic position as of Q2 2021 after selling out during the quarter.
Michael Gelband sold 1,529 Immunic shares in Q2 2021, an estimated $244K.
Michael Gelband first reported a position in Immunic in Q2 2020 and held it in 2 quarters.
Michael Gelband's Immunic position peaked at $244K in Q1 2021.
60 funds tracked by Wall St. Rank held Immunic as of Q2 2021.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.